Radiotherapy after chemotherapy for metastatic seminoma - A diminishing role

European Journal of Cancer Part A

Volumn 33, Issue 6, 1997, Pages 829-835

  Duchesne, G M ^a,l   Stenning, S P ^b   Aass, N ^c   Mead, G M ^d   Fossa S D ^c   Oliver, R T D ^e   Horwich, A ^f   Read, G ^g   Roberts, I T ^h   Rustin, G ⁱ   Cullen, M H ^j   Kaye, S B ^k   Harland, S J ^a   Cook, P A ^b  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h Northern Centre for Cancer Treatment   (United Kingdom)

ⁱ MOUNT VERNON HOSPITAL   (United Kingdom)

^j QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^k BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^l PETER MACCALLUM CANCER CENTRE   (Australia)

more..

Author keywords

Cisplatin; Metastatic seminoma; Postchemotherapy radiotherapy

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSAY; BINDING SITE; CLINICAL TRIAL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; SEMINOMA; SURVIVAL RATE; TREATMENT PLANNING;

ABDOMINAL NEOPLASMS; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; DISEASE PROGRESSION; ETOPOSIDE; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SEMINOMA; SURVIVAL RATE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 18144447926     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00033-6     Document Type: Article

References (25)

1. Peckham MJ, McElwain TJ, Barrett A, et al. Combined management of the malignant teratoma of the testis. Lancet 1979, 2, 267-270.
2. Marks LB, Anscher MS, Shipley WU. The role of radiation therapy in the treatment of testicular germ cell tumors. Haematol Oncol Clinics N Am 1991, 5, 1143-1172.
3. Smalley SR, Evans RG, Richardson RL, et al. Radiotherapy as initial treatment for bulky Stage II testicular seminomas. J Clin Oncol 1985, 3, 1333-1338.
4. Fossa SD, Droz J, Stoter G, et al. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma. Results of the EORTC Trial 30874. Br J Cancer 1995, 71, 619-624.
5. Motzer RJ, Bosl GJ, Geller NJ, et al. Advanced seminoma: the role of chemotherapy and adjunctive surgery. Ann Intern Med 1988, 108, 513-518.
6. Horwich A, Dearnaley DP, A'Hern A, et al. The activity of single-agent carboplatin in advanced seminoma. Eur J Cancer 1992, 28A, 1307-1310.
7. Peckham MJ, Horwich A, Hendry WF. Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br J Cancer 1985, 52, 7-13.
8. Motzer R, Bosl GJ, Heelan R, et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systematic chemotherapy. J Clin Oncol 1987, 5, 1064-1070.
9. Puc HS, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996, 14, 454-460.
10. Schultz SM, Einhorn LH, Dewey JCJ, et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 1989, 7, 1497-1503.
11. Warren GP, Einhorn LH. Gallium scans in the evaluation of residual masses after chemotherapy for seminoma. J Clin Oncol 1995, 13, 2784-2788.
12. Horwich A, Dearnaley D, Duchesne G, et al. Simple non-toxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol 1989, 7, 1150-1156.
13. MacVicar D, Horwich A. Sites of relapse in seminoma treated with single agent carboplatin chemotherapy: implications for further management. Clin Oncol 1992, 4, 209-213.
14. Thomas GM, Rider WD, Dembo AJ, et al. Seminoma of the testis: results of treatment and patterns of failure after radiation therapy. Int J Radiat Oncol 1982, 8, 165-174.
15. Thomas G, Jones W, VanOosterom A, Kawai T. Consensus statement on the investigation and management of testicular seminoma 1989. Prog Clin Biol Res 1990, 357, 285-294.
16. Babaian RJ, Zagars GK. Testicular seminoma: the MD Anderson experience. An analysis of pathological and patient characteristics, and treatment recommendations. J Urol 1988, 139, 311-314.
17. Lederman GS, Herman TS, Jochelson M, et al. Radiation therapy of seminoma: 17-year experience at the Joint Center for Radiation Therapy. Radiother Oncol 1989, 14, 203-208.
18. Horwich A, Oliver RTD, Fossa SD, Wilkinson P, Mead GM, Stenning S on behalf of the UK MRC Testicular Tumour Working Party. 1996. Proc Am Assoc Clin Oncol 1996, 15, 258 (abstract).
19. Einhorn LH, Williams SD. Chemotherapy of disseminated seminoma. Cancer Clin Trials 1980, 3, 307-313.
20. Oliver RT, Love S, Ong J. Alternatives to radiotherapy in the management of seminoma. Br J Urol 1990, 65, 61-67.
21. Fossa S, Borge L, Aass N, et al. The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol 1987, 5, 1071-1077.
22. Loehrer PJ Sr, Birch R, William SD, et al. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 1987, 5, 1212-1220.
23. Kumar L. Epipodophyllotoxins and secondary leukaemia. Lancet 1993, 342, 819-820.
24. Bokemeyer C, Schmoll H-J. Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 1995, 13, 283-292.
25. Aass N, Kaasa S, Lund E, et al. Long-term somatic side-effects and morbidity in testicular cancer patients. Br J Cancer 1990, 61, 151-155.